dexketoprofen trometamol‘s R&D Progress
Dexketoprofen Trometamol is a small molecule drug that targets both COX-1 and COX-2 enzymes. It falls under the therapeutic area of Nervous System Diseases and is primarily used to treat various types of pain, including postoperative pain, migraine disorders, back pain, and renal colic.
The drug has received approval in multiple countries, including the United Kingdom, where it was first approved in January 1998. It has reached the highest phase of development which is approved globally.
As a nonsteroidal anti-inflammatory drug (NSAID), Dexketoprofen Trometamol works by inhibiting the activity of COX enzymes, which are responsible for the production of prostaglandins, substances that play a role in pain and inflammation. By blocking these enzymes, the drug helps alleviate pain and reduce inflammation in patients suffering from various conditions.
The highest R&D phase of this drug is approved. Its approval for the treatment of pain, particularly postoperative pain, indicates its potential to provide relief to patients recovering from surgical procedures. Additionally, its approval for migraine disorders suggests its effectiveness in managing the debilitating symptoms associated with this condition.
The drug’s approval for back pain and renal colic further highlights its potential to address different types of pain, including those caused by musculoskeletal issues and kidney stones. This versatility makes Dexketoprofen Trometamol a valuable option for healthcare professionals seeking effective pain management solutions.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for dexketoprofen trometamol: COX-1 inhibitors COX-2 inhibitors
COX-1 inhibitors and COX-2 inhibitors are types of drugs that target specific enzymes involved in inflammation and pain.
COX stands for Cyclooxygenase, which is an enzyme responsible for the production of prostaglandins, substances that play a role in inflammation, pain, and fever. There are two isoforms of the COX enzyme: COX-1 and COX-2.
COX-1 inhibitors specifically target and inhibit the COX-1 enzyme. COX-1 is constitutively expressed in many tissues and is involved in maintaining normal physiological functions, such as protecting the stomach lining, regulating blood flow to the kidneys, and promoting platelet aggregation. By inhibiting COX-1, these drugs can reduce pain and inflammation but may also cause side effects such as gastrointestinal ulcers and bleeding due to the inhibition of the protective functions of COX-1.
COX-2 inhibitors, on the other hand, selectively target and inhibit the COX-2 enzyme. COX-2 is primarily induced during inflammation and is responsible for the production of prostaglandins that contribute to pain and inflammation. By specifically inhibiting COX-2, these drugs can effectively reduce inflammation and pain while minimizing the risk of gastrointestinal side effects associated with COX-1 inhibition. COX-2 inhibitors are commonly used in the treatment of conditions like arthritis, where inflammation plays a significant role.
It is important to note that the use of COX-1 and COX-2 inhibitors should be done under medical supervision, as these drugs can have different effects on various physiological processes and may interact with other medications.
Drug Target R&D Trends for dexketoprofen trometamol
COX-1 and COX-2 are enzymes involved in the production of prostaglandins, which are important mediators of inflammation and pain in the human body. COX-1 is constitutively expressed in various tissues and plays a crucial role in maintaining normal physiological functions, such as protecting the stomach lining and regulating blood clotting. On the other hand, COX-2 is induced during inflammation and is responsible for producing prostaglandins that contribute to pain, swelling, and fever. Understanding the distinct roles of COX-1 and COX-2 is essential for developing drugs that selectively target these enzymes, providing relief from inflammation and pain while minimizing unwanted side effects.
According to Patsnap Synapse, as of 6 Sep 2023, there are a total of 33 COX-1 + COX-2 drugs worldwide, from 68 organizations, covering 61 indications, and conducting 886 clinical trials.
The analysis of the current competitive landscape and future development of target COX-1 + COX-2 reveals a strong focus on developing drugs by companies such as AbbVie, Inc., Viatris Inc., A. Menarini Industrie Farmaceutiche Riunite SRL, and Assertio Holdings, Inc. The indications targeted by these drugs include pain, postoperative pain, rheumatoid arthritis, osteoarthritis, inflammation, acute pain, low back pain, and various other conditions. Small molecule drugs are the most rapidly progressing drug type under this target. The United States, Japan, and the European Union are leading in terms of development, with China also showing progress. Overall, the target COX-1 + COX-2 presents a competitive landscape with a wide range of indications and drug types, indicating potential for future advancements in the pharmaceutical industry.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
Overall, Dexketoprofen Trometamol is a small molecule drug that targets COX-1 and COX-2 enzymes. Its approval in multiple countries, including the United Kingdom, for various indications related to pain demonstrates its efficacy and potential to provide relief to patients suffering from different types of pain. As a widely recognized and accepted drug, Dexketoprofen Trometamol holds promise in the field of biomedicine and offers healthcare professionals a valuable tool in managing pain associated with various conditions.
